The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer
Author:
Affiliation:
1. The James Buchanan Brady Urological Institute; The Johns Hopkins University School of Medicine; Baltimore Maryland 21287
2. GTx Inc.; Memphis Tennessee 38103
Funder
National Cancer Institute
National Institutes of Health
Publisher
Wiley
Subject
Cell Biology,Molecular Biology,Biochemistry
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/jcb.25091/fullpdf
Reference40 articles.
1. Multiple drug resistance mechanisms in cancer;Baguley;Mol Biotechnol,2010
2. MDR1 (ABCB1) polymorphisms: functional effects and clinical implications;Brambila-Tapia;Rev Invest Clin,2013
3. Taxol-requiring mutant of Chinese hamster ovary cells with impaired mitotic spindle assembly;Cabral;J Cell Biol,1983
4. Conserved oncogenic behavior of the FAM83 family regulates MAPK signaling in human cancer;Cipriano;Mol Cancer Res,2014
5. MAP kinase signalling pathways in cancer;Dhillon;Oncogene,2007
Cited by 86 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. mTOR inhibitor introduce disitamab vedotin (RC48-ADC) rechallenge microtubule-chemotherapy resistance in HER2-low MBC patients with PI3K mutation;Frontiers in Oncology;2024-01-25
2. Dual inhibition of MEK and PI3Kβ/δ–a potential therapeutic strategy in PTEN-wild-type docetaxel-resistant metastatic prostate cancer;Frontiers in Pharmacology;2024-01-22
3. Comparing efficacy of first-line treatment of metastatic castration resistant prostate cancer: a network meta-analysis of randomized controlled trials;Frontiers in Pharmacology;2023-11-22
4. Tannic Acid and Ethyl Gallate Potentialize Paclitaxel Effect on Microtubule Dynamics in Hep3B Cells;Pharmaceuticals;2023-11-08
5. Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer;Cancers;2023-10-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3